- Home
- JBGS vs KURA Comparison
JBGS vs KURA Comparison
Compare JBGS & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JBGS | KURA |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 823.7M | 841.6M |
| IPO Year | 2017 | 2015 |
Fundamental Metrics
Financial Performance| Metric | JBGS | KURA |
|---|---|---|
| Price | $12.14 | $9.28 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 1 | 11 |
| Target Price | $15.00 | ★ $25.56 |
| AVG Volume (30 Days) | 646.8K | ★ 1.2M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.69% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $498,598,000.00 | $67,482,000.00 |
| Revenue This Year | N/A | $28.28 |
| Revenue Next Year | N/A | $106.37 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $11.32 | $5.45 |
| 52 Week High | $24.30 | $12.49 |
Technical Indicators
Market Signals| Indicator | JBGS | KURA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout JBGS JBG SMITH Properties
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party real estate services. It generates maximum revenue from the commercial segment.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.